Digital pills cut blood pressure faster
Patients with uncontrolled hypertension and type 2 diabetes using digital medicines had larger 4-week SBP drops than usual care.
Source
Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hypertension and Type 2 Diabetes: Prospective, Open-Label, Cluster-Randomized Pilot Clinical Trial
What they did
A 12-week open-label cluster-randomized three-arm pilot at 13 US primary-care sites compared 4-week DMO, 12-week DMO, and usual care for uncontrolled HTN with T2DM.
What they found
DMO users had about 9 mm Hg greater SBP reduction by week 4, more patients at BP goal by week 12, and larger LDL-C declines; HbA1c also trended lower.
The limits
What it doesn't show
Long-term hard cardiovascular events, blinded placebo effects, or performance outside motivated primary-care clusters.
Key terms
- DMO
- Digital medicine offering—sensor-enabled medicines with adherence feedback.
- SBP
- Systolic blood pressure, the primary endpoint at week 4.
- Cluster randomization
- Sites—not individual patients—assigned to study arms.
- Modified ITT
- Analysis set after excluding a compromised usual-care site.
- LDL-C
- Low-density lipoprotein cholesterol, an exploratory lipid outcome.
- Uncontrolled HTN
- Blood pressure above target despite available treatments.
Flashcards
Want these cards to stick?
Save the deck to NoteFren and study it with spaced repetition.
Quiz yourself
Primary endpoint was:
Common questions
What was the primary endpoint?
Change in SBP from baseline to week 4.
How large was the analytic sample?
109 participants in the modified-ITT set.
How much greater was SBP reduction?
About 9 mm Hg greater with DMO by week 4.
What happened to LDL-C?
Greater reductions with DMO (−33.2 at week 4; −19.2 at week 12 vs usual care).
More on Treatment adherence